Bubs Australia marks over 2-month high on clinical data submission to US FDA

Bubs Australia

16/06/2025 04:38

** Shares of infant formula maker Bubs Australia BUB.AX rise 3.1% to A$0.165, their highest since April 9

** Co submits clinical trial data to U.S. Food and Drug Administration for all three of its infant milk formulas by lodging New Infant Formula Submission (NIFS) with the regulatory body

** "The submission of our NIFS represents an important milestone for Bubs in our journey to obtain permanent market access for the USA" - co

** About 4.4 mln shares change hands, 2.1x the 30-day average of 2.1 mln

** Stock up 65% YTD, including moves in current session

 (Reporting by Jasmeen Ara Shaikh in Bengaluru)

 ((JasmeenAraIslam.Shaikh@thomsonreuters.com;))